Previous Close | 0.8470 |
Open | 0.7900 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.8470 - 0.8470 |
52 Week Range | 0.7200 - 1.1000 |
Volume | |
Avg. Volume | 3,822 |
Market Cap | 19.448M |
Beta (5Y Monthly) | 0.52 |
PE Ratio (TTM) | 28.23 |
EPS (TTM) | 0.0300 |
Earnings Date | Jun 12, 2024 - Jun 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 29, 2024 |
1y Target Est | 1.70 |
Subscribe to Yahoo Finance Plus to view Fair Value for PBSV
By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced results for the quarter ended January 31, 2024. The headline was below expectations and management noted that the company was “challenged” in the quarter. Management didn’t elaborate on what those challenges were, but all geographical segments of the company’s business suffered losses and saw
DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, ...
By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced its full year 2023 (October) results. The headline showed that earnings per share of $0.06 were slightly below our estimates as revenues dropped modestly from the previous year. However, the company continues to report continued impressive improvement in gross margin on sales revenue by 4.6%